Oncology News

Digestive Disease Week 2023 in Chicago may have ended in early May, but Healio coverage has continued all month long. Wondering what you missed and what is coming next? Healio recaps the biggest meeting news making waves in the specialty.

The American Cancer Society estimates 106,970 new cases of colon cancer and 46,050 new cases of rectal cancers in the United States in 2023, with colorectal cancer expected to result in approximately 52,550 deaths this year alone.

UnitedHealthcare halted its controversial prior authorization policy for gastroenterology endoscopy services, set to start on June 1, opting instead to move forward with an advanced notification program.

CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a study presented at ASCO Annual Meeting.

CHICAGO — The odds of having gastric and pancreatic cancers were higher among postmenopausal women on hormone replacement therapy and remained significant after controlling for risk factors, according to data at Digestive Disease Week.

CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.

CHICAGO — Most patients with intermediate-risk rectal cancer can undergo curative-intent treatment without the need for pelvic radiation, according to study results presented during a press conference at ASCO Annual Meeting.

CHICAGO — Individuals with high-risk hepatocellular carcinoma undergoing curative-intent procedures did not experience clinically meaningful deterioration in quality of life or function after adjuvant therapy, phase 3 study results showed.

CHICAGO — Neoadjuvant FOLFIRINOX chemotherapy failed to extend OS compared with upfront surgery for patients with resectable pancreatic head cancer, according to study results presented at ASCO Annual Meeting.

CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.